Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lambda Light Chain Antibody [ICO-106] | Login | Lambda Light Chain Antibody [ICO-106] | ||||||||||||||||
|
||||||||||||||||||
| Insulin Antibody [2D11-H5 or INS05] | Login | Insulin Antibody [2D11-H5 or INS05] | ||||||||||||||||
|
||||||||||||||||||
| CD11c Antibody [HC1/1] | Login | CD11c Antibody [HC1/1] | ||||||||||||||||
|
||||||||||||||||||
| VEGFR2 Antibody [KDR721] | Login | VEGFR2 Antibody [KDR721] | ||||||||||||||||
|
||||||||||||||||||
| Cytokeratin 8 Antibody [K8/383] | Login | Cytokeratin 8 Antibody [K8/383] | ||||||||||||||||
|
||||||||||||||||||
| Cytokeratin 8 Antibody [TS1] | Login | Cytokeratin 8 Antibody [TS1] | ||||||||||||||||
|
||||||||||||||||||
| KRT8 Antibody [K8.8] | Login | KRT8 Antibody [K8.8] | ||||||||||||||||
|
||||||||||||||||||
| Cytokeratin 10 Antibody [LH2] | Login | Cytokeratin 10 Antibody [LH2] | ||||||||||||||||
|
||||||||||||||||||
| Cytokeratin 14 Antibody [LL002] | Login | Cytokeratin 14 Antibody [LL002] | ||||||||||||||||
|
||||||||||||||||||
| Cytokeratin 19 Antibody [A53-B/A2.26] | Login | Cytokeratin 19 Antibody [A53-B/A2.26] | ||||||||||||||||
|
||||||||||||||||||
| L1CAM Antibody [UJ127] | Login | L1CAM Antibody [UJ127] | ||||||||||||||||
|
||||||||||||||||||
| EpCAM Antibody [323/A3] | Login | EpCAM Antibody [323/A3] | ||||||||||||||||
|
||||||||||||||||||
| MUC18 Antibody [OJ79c] | Login | MUC18 Antibody [OJ79c] | ||||||||||||||||
|
||||||||||||||||||
| CD46 Antibody [122.2] | Login | CD46 Antibody [122.2] | ||||||||||||||||
|
||||||||||||||||||
| MUC5AC Antibody [45M1] | Login | MUC5AC Antibody [45M1] | ||||||||||||||||
|
||||||||||||||||||
| NCAM Antibody [123C3.D5] | Login | NCAM Antibody [123C3.D5] | ||||||||||||||||
|
||||||||||||||||||
| NKX2.2 Antibody [NX2/294] | Login | NKX2.2 Antibody [NX2/294] | ||||||||||||||||
|
||||||||||||||||||
| ODC-1 Antibody [ODC1/485] | Login | ODC-1 Antibody [ODC1/485] | ||||||||||||||||
|
||||||||||||||||||
| PAX6 Antibody [PAX6/498] | Login | PAX6 Antibody [PAX6/498] | ||||||||||||||||
|
||||||||||||||||||
| PAX7 Antibody [PAX7/497] | Login | PAX7 Antibody [PAX7/497] | ||||||||||||||||
|
||||||||||||||||||
| PECAM-1 Antibody [C31.7] | Login | PECAM-1 Antibody [C31.7] | ||||||||||||||||
|
||||||||||||||||||
| CD31 Antibody [C31.3] | Login | CD31 Antibody [C31.3] | ||||||||||||||||
|
||||||||||||||||||
| PLGF Antibody [PLGF94] | Login | PLGF Antibody [PLGF94] | ||||||||||||||||
|
||||||||||||||||||
| Progesterone Receptor Antibody [PR484] | Login | Progesterone Receptor Antibody [PR484] | ||||||||||||||||
|
||||||||||||||||||
| Progesterone Receptor Antibody [PR500] | Login | Progesterone Receptor Antibody [PR500] | ||||||||||||||||
|
||||||||||||||||||


